The advent of immunotherapy based on immune checkpoint inhibitors has improved the treatment of advanced hepatocellular ...

CURE spoke with an expert about the potential positive effects of radiation therapy for patients with hepatocellular carcinoma.

Researchers at Mount Sinai have made a breakthrough in treating a type of liver cancer called hepatocellular carcinoma (HCC).

Evan Seigerman, an analyst from BMO Capital, has initiated a new Buy rating on Replimune Group (REPL).Stay Ahead of the Market:Discover ...

The FDA granted orphan drug designation to amezalpat in hepatocellular carcinoma based on phase 1b/2 data showing efficacy ...

The following is a summary of “Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, ...

Background: Hepatoblastoma (HBL) and hepatocellular carcinoma (HCC) are respectively the first and the second most common pediatric malignant liver tumors. The purpose of this study was to ...

Researchers at Mount Sinai have made a breakthrough in treating a type of liver cancer called hepatocellular carcinoma (HCC).

Scientists have made a discovery which could lead to the first change in standard liver cancer treatment in 20 years. Two ...

Future Oncol. 2013;9(10):1533-1548. The dual targeting of VEGF and EGFR was considered a logical treatment approach. Many data from Phase II studies have suggested that erlotinib may facilitate ...

Adding durvalumab and bevacizumab to transarterial chemoembolization improved responses and progression-free survival.

Two independent studies reveal that disease progression is delayed by combining two targeted therapies with the traditional ...